8058 Zurich-Airport, ch
+41 (43) 21142-30
The Annual General Meeting of Nobel Biocare approves all proposals of the Board of Directors
Among others, the Annual General Meeting approved a dividend of CHF 0.20 gross per registered share of CHF 0.40 nominal value. The dividend will be paid on 8 April 2013 (ex-dividend day: 3 April 2013; record date: 5 April 2013) in a shareholder-friendly way without deduction of withholding tax.
All Board members proposed for re-election were re-elected: Daniela Bosshardt-Hengartner, Raymund Breu, Edgar Fluri, Michel Orsinger, Juha Räisänen, Oern Stuge, Rolf Watter and Georg Watzek.
Franz Maier was elected as a new Board member.
According to the by-laws, all Board members have been elected for a one-year term.
At the first board meeting following the Annual General Meeting, Rolf Watter was re-elected Chairman of the Board and Raymund Breu was re-elected Vice-Chairman of the Board. The Board committees will be chaired by Oern Stuge (Innovation and Technology), Edgar Fluri (Audit), Juha Räisänen (Operations and Process Excellence), Rolf Watter (Nomination and Compensation) and Michel Orsinger (Strategy (newly established committee)).
KPMG, Zurich, has been re-elected as auditors for the financial year 2013.
The next Annual General Meeting of the shareholders will be convened on March 26, 2014.
Financial reporting calendar 2013:
Interim Report 1, 2013 April 25, 2013
Interim Report 2, 2013 August 22, 2013
Interim Report 3, 2013 November 7, 2013
Full Year Report 2013 February 18, 2014
This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.